Clinical Advances in the Management of Myopia and Its Complications

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: closed (25 March 2024) | Viewed by 973

Special Issue Editor


E-Mail Website
Guest Editor
NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK
Interests: children’s eye health; myopia; amblyopia; ocular surface inflammation

Special Issue Information

Dear Colleagues,

On behalf of the Journal of Clinical Medicine editorial team, I am delighted to present the Special Issue “Clinical Advances in the Management of Myopia and Its Complications”.

Of the 8 billion people in the global population, around 30% have myopia—around 2.5 billion people. High myopia affects over 400 million. Eye care practitioners worldwide see the impact of this development, with adults of working age and older suffering from sight-threatening complications and irreversible sight loss with devastating effects on quality of life. At the same time, practitioners providing care for children and teenagers see increasing numbers of young children with early onset and fast-progressing myopia. Environmental and behavioural changes—urbanisation and the ever-increasing use of near-work and screens—appears to drive an increase in prevalence, but is there a way to reverse these developments? Refractive errors are a WHO priority eye disease, and worldwide, efforts are underway to raise awareness and reduce the risk of myopia onset and progression.
This Special Issue collates original high-quality articles along the significant axes of the myopia discussion:

  • Myopia management across people’s lives: from preschoolers to schoolchildren, adolescents, young adults and adults;
  • The management of myopia at different levels of severity, from pre-myopia through low to high, pathological and syndromic myopia;
  • The diagnosis, monitoring and interventions to treat myopia-associated complications such as retinal breaks and detachments, myopic maculopathy and myopic optic neuropathy.

Dr. Annegret Dahlmann-Noor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myopia
  • pre-myopia
  • high myopia
  • pathological myopia
  • syndromic myopia
  • child
  • adolescent
  • young adult
  • adult
  • myopic maculopathy
  • myopic macular degeneration
  • retinal break
  • retinal tear
  • retinal detachment
  • myopic optic neuropathy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 375 KiB  
Article
Efficacy and Safety of 0.03% Atropine Eye Drops in Controlling Myopia Progression: A One-Year Prospective Clinical Study
by Dovile Simonaviciute, Andrzej Grzybowski, Arvydas Gelzinis and Reda Zemaitiene
J. Clin. Med. 2024, 13(11), 3218; https://doi.org/10.3390/jcm13113218 - 30 May 2024
Viewed by 729
Abstract
Objective: To investigate the efficacy and safety of one-year treatment with 0.03% atropine eye drops for slowing myopia progression among children aged 6–12 years. Methods: Healthy Caucasian children aged 6–12 years with cycloplegic spherical equivalent (SE) from −1.0 D to −5.0 D and [...] Read more.
Objective: To investigate the efficacy and safety of one-year treatment with 0.03% atropine eye drops for slowing myopia progression among children aged 6–12 years. Methods: Healthy Caucasian children aged 6–12 years with cycloplegic spherical equivalent (SE) from −1.0 D to −5.0 D and astigmatism and anisometropia ≤1.5 D were included. Changes in mean axial length (AL) and objective SE as well as changes in intraocular pressure (IOP), central corneal thickness (CCT), anterior chamber depth (ACD) and lens thickness (LT) were assessed in the 0.03% atropine eye drops group and the control group from baseline through the 1-year follow-up. The proportion of participants showing myopia progression of <0.5 D from baseline in each group and any potential side effects in 0.03% atropine group were evaluated. Results: The study involved 31 patients in the 0.03% atropine eye drops group and 41 in the control group. Administration of 0.03% atropine for 1 year resulted in a mean change in SE of −0.34 (0.44) D/year, significantly lower than the −0.60 (0.50) D/year observed in the control group (p = 0.024). The change in AL was 0.19 (0.17) mm in the 0.03% atropine group, compared to 0.31 (0.20) mm in the control group (p = 0.015). There were no significant differences in changes of IOP, CCT and LT between the groups (all p ≥ 0.05). The 0.03% atropine group had a significantly greater increase in ACD compared to the control group (p = 0.015). In total, 64.5% of patients in the 0.03% atropine group showed progression <0.5 D/year, in contrast to 39.0% in the control group (p = 0.032). Adverse events were reported in 13 (35.0%) out of 37 patients in the treatment group, leading to discontinuation of the eye drops in six (16.0%) cases. None of the adverse events were severe. Conclusions: Despite a higher incidence of adverse events, 0.03% atropine eye drops effectively slowed the progression of myopia over 1-year. Full article
(This article belongs to the Special Issue Clinical Advances in the Management of Myopia and Its Complications)
Show Figures

Figure 1

Back to TopTop